Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients

World Journal of Gastroenterology

Volumn 17, Issue 30, 2011, Pages 3510-3517

  Moon, Hyung Hwan ^a   Seo, Kyung Won ^a   Yoon, Ki Young ^a   Shin, Yeon Myung ^a   Choi, Kyung Hyun ^a   Lee, Sang Ho ^a  

^a Kosin University College of Medicine   (South Korea)

Author keywords

Acute renal failure; Cisplatin; Drug toxiities; Nephrotoxicity

Indexed keywords

AMIFOSTINE; CAPECITABINE; CISPLATIN; CREATININE; DIURETIC AGENT; DOCETAXEL; FLUOROURACIL; FUROSEMIDE; IRINOTECAN; MANNITOL; MITOMYCIN C; PACLITAXEL;

ACUTE KIDNEY FAILURE; ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIURESIS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYDRATION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; STOMACH CANCER; TREATMENT OUTCOME;

EID: 80052534028     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i30.3510     Document Type: Review

References (30)

1. Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis 1986; 8: 356-367
2. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 1993; 50: 147-158
3. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatinassociated nephrotoxicity and pathological events. Contrib Nephrol 2005; 148: 107-121
4. Srivastava RC, Farookh A, Ahmad N, Misra M, Hasan SK, Husain MM. Reduction of cis-platinum induced nephrotoxicity by zinc histidine complex: the possible implication of nitric oxide. Biochem Mol Biol Int 1995; 36: 855-862
5. Finley RS, Fortner CL, Grove WR. Cisplatin nephrotoxicity: a summary of preventative interventions. Drug Intell Clin Pharm 1985; 19: 362-367
6. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008; 61: 903-909
7. Kovach JS, Moertel CG, Schutt AJ, Reitemeier RG, Hahn RG. Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep 1973; 57: 357-359
8. Higby DJ, Wallace HJ, Holland JF. Cis-diamminedichloroplatinum (NSC-119875): a phase I study. Cancer Chemother Rep 1973; 57: 459-463
9. Kuan Y, Hossain M, Surman J, El Nahas AM, Haylor J. GFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease. Nephrol Dial Transplant 2005; 20: 2394-2401
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
12. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-999
13. Buitrago F, Calvo JI, Gómez-Jiménez C, Cañón L, Robles NR, Angulo E. Comparison and agreement of the Cockcroft- Gault and MDRD equations to estimate glomerular filtration rate in diagnosis of occult chronic kidney disease. Nefrologia 2008; 28: 301-310
14. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147
15. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384
16. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int 2008; 73: 538-546
17. Bagshaw SM, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23: 1569-1574
18. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464
19. Maniccia-Bozzo E, Espiritu MB, Singh G. Differential effects of cisplatin on mouse hepatic and renal mitochondrial DNA. Mol Cell Biochem 1990; 94: 83-88
20. Salazar I, Tarrago-Litvak L, Gil L, Litvak S. The effect of benzo[a]pyrene on DNA synthesis and DNA polymerase activity of rat liver mitochondria. FEBS Lett 1982; 138: 45-49
21. Aass N, Fosså SD, Aas M, Lindegaard MW. Renal function related to different treatment modalities for malignant germ cell tumours. Br J Cancer 1990; 62: 842-846
22. Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care 2005; 11: 555-565
23. Grau JJ, Estapé J, Cuchi MA, Fírvida JL, Blanch JL, Ascaso C. Calcium supplementation and ototoxicity in patients receiving cisplatin. Br J Clin Pharmacol 1996; 42: 233-235
24. Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981; 95: 628-632
25. Uozumi J, Koikawa Y, Yasumasu T, Tokuda N, Kumazawa J. The protective effect of methylprednisolone against cisplatin- induced nephrotoxicity in patients with urothelial tumors. Int J Urol 1996; 3: 343-347
26. Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990;100: 724-734
27. Heidemann HT, Gerkens JF, Jackson EK, Branch RA. Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Naunyn Schmiedebergs Arch Pharmacol 1985; 329: 201-205
28. Litterst CL, LeRoy AF, Guarino AM. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals. Cancer Treat Rep 1979; 63: 1485-1492
29. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43: 14-34
30. Merouani A, Davidson SA, Schrier RW. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol 1997; 17: 53-58